- Home
- POM vs ALZN Comparison
POM vs ALZN Comparison
Compare POM & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POM | ALZN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | POM | ALZN |
|---|---|---|
| Price | $0.71 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 14.9K | ★ 106.7K |
| Earning Date | 05-11-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.84 |
| 52 Week High | $6.43 | $2.68 |
Technical Indicators
Market Signals| Indicator | POM | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 66.22 |
| Support Level | $0.23 | $1.69 |
| Resistance Level | $1.17 | $2.25 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 26.99 | 84.54 |
Price Performance
Historical ComparisonAbout POM POMDOCTOR LIMITED American Depositary Shares
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.